Posted on 20/10/2008 in Pharmaceutical Company Product News Boehringer Ingelheim has announced that physicians and patients could have several new type 2 diabetes treatment alternatives in the next couple of years.
The company unveiled a pipeline of oral anti-diabetic compounds in phases II and III at its second international research and development press conference, which it states establishes it in the type 2 diabetes arena.
Dr Andreas Barner, vice-chairman of the company's board of managing directors, responsible for research, development and medicine, stated it is a "great pleasure" for Boehringer Ingelheim to be able to report in its research and development processes.
"Boehringer Ingelheim is scientifically, economically and intellectually well prepared to successfully broadening its diabetes pipeline to meet the needs of physicians and their patients," he added.
Professor Klaus Dugi, corporate vice-president of medical affairs at the company, states the firm's work into developing new treatment options for people suffering from type 2 diabetes began in 2001 and it now "bearing fruit".
He said this is especially important as, despite a range of treatment options being available, patients still struggle with tolerability.
In recent days, Boehringer Ingelheim noted that Dr Esther Barreiro won the 2008 European Respiratory Society annual award for chronic obstructive pulmonary disease, of which it is the sponsor.Other news stories from 20/10/2008
Read more in the Zenopa News Archive
How this news is generated
|
